<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240916063055N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-10-10</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of two different anesthesia methods with Remifentanil and Dexmedetomidine on the amount of bleeding during surgery and the visual in endoscopic sinus surgeries</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of two different anesthesia methods with Remifentanil and Dexmedetomidine on the amount of bleeding during surgery and the visual in endoscopic sinus surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/79136</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly allocated into 2 groups by block randomization. In this technique, 5 blocks of size 4, 6, and 8 will be selected randomly for patients of 2 groups A and B.  
patients will be allocated randomly and equally into 2 groups. block sequence will be prepare by www.sealedenvelope.com, Blinding description: Drugs are provided in the form of similar 50ml syringes by the first person, these drugs, which have the same color and size and in similar colors, are injected by the second person who is completely unaware of the contents of the syringes. The anesthesiologist, patients, and other personnel involved in the work are blinded to the drugs injected in this study. This study is double-blind.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Endoscopic sinus.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The surgical technique is the same for all patients and will be performed by a specific surgeon, but two different anesthetic formulas are used. Remifentanil (Elixir Pharmaceutical Company) is started at an intravenous infusion rate of 0.25 μg/kg simultaneously with induction of anesthesia. After that, Midazolam (Aborehan Pharmaceutical Company) 0.04mg/kg, Fentanyl (Jahan Behbohd Company) 2µg/kg and Morphine (Alborz Daro Pharmaceutical Company) 10mg/kg as premedication and Propofol  (Terman Yab Daro Company)  2-2.5µg/kg  and Atracurium(Daro Pakhsh Company) 0.15mg/kg will be used to induce anesthesia. Maintenance is started with Propofol (100μg/kg/min). Intervention 2: Control group: The surgical technique is the same for all patients and will be performed by a specific surgeon, but two different anesthetic formulas are used. Dexmedetomidine (Arang daro darman Company) 1μg/kg intravenous bolus dose during 20 minutes before induction of anesthesia and then continue with infusion rate of 0.4-0.8μg/kg/hr simultaneously with induction of anesthesia. After that, Midazolam (Aborehan Pharmaceutical Company) 0.04mg/kg, Fentanyl (Jahan Behbohd Company) 2µg/kg and Morphine (Alborz Daro Pharmaceutical Company) 10mg/kg as premedication and Propofol  (Terman Yab Daro Company)  2-2.5µg/kg  and Atracurium(Daro Pakhsh Company) 0.15mg/kg will be used to induce anesthesia. Maintenance is started with Propofol (100μg/kg/min).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is It is against our policy.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Farnoosh Firouzi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Faghihi Hospital, Zand Street.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134844119</zip>
        <telephone>+98 71 3647 4270</telephone>
        <email>f.firoozi۱۹۹۰@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nima Naderi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Anesthesiology Department, Faghihi Hospital, Zand Street.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193711351</zip>
        <telephone>+98 71 3647 4270</telephone>
        <email>nima_naderi۵۴@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Adult patients with ASA grade I or II (American Society of Anesthesiology classification)
Adult patients between 18 and 70 years old
Adult patients who are candidates for sinus endoscopy</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to the drugs used in the study
Positive history of kidney, liver, addiction and bleeding diseases.
Obesity (BMI &gt; 40)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J32</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic sinusitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The surgical technique is the same for all patients and will be performed by a specific surgeon, but two different anesthetic formulas are used. Remifentanil (Elixir Pharmaceutical Company) is started at an intravenous infusion rate of 0.25 μg/kg simultaneously with induction of anesthesia. After that, Midazolam (Aborehan Pharmaceutical Company) 0.04mg/kg, Fentanyl (Jahan Behbohd Company) 2µg/kg and Morphine (Alborz Daro Pharmaceutical Company) 10mg/kg as premedication and Propofol  (Terman Yab Daro Company)  2-2.5µg/kg  and Atracurium(Daro Pakhsh Company) 0.15mg/kg will be used to induce anesthesia. Maintenance is started with Propofol (100μg/kg/min).</i_keyword>
      <i_keyword>Control group: The surgical technique is the same for all patients and will be performed by a specific surgeon, but two different anesthetic formulas are used. Dexmedetomidine (Arang daro darman Company) 1μg/kg intravenous bolus dose during 20 minutes before induction of anesthesia and then continue with infusion rate of 0.4-0.8μg/kg/hr simultaneously with induction of anesthesia. After that, Midazolam (Aborehan Pharmaceutical Company) 0.04mg/kg, Fentanyl (Jahan Behbohd Company) 2µg/kg and Morphine (Alborz Daro Pharmaceutical Company) 10mg/kg as premedication and Propofol  (Terman Yab Daro Company)  2-2.5µg/kg  and Atracurium(Daro Pakhsh Company) 0.15mg/kg will be used to induce anesthesia. Maintenance is started with Propofol (100μg/kg/min).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding during surgery. Timepoint: During the surgery. Method of measurement: Based on the estimate of sterile gases used and Measuring the volume of the suction device.</prim_outcome>
      <prim_outcome>Postoperative nausea and vomiting. Timepoint: Recovery and at the time of arrival and every 30 minutes. Method of measurement: Based on scoring (0=no nausea and vomiting, 1=nausea, 2=vomiting and 3=vomiting more than 2 times).</prim_outcome>
      <prim_outcome>Pain after surgery. Timepoint: Recovery and at the time of arrival and every 20 minutes. Method of measurement: Visual pain scale questionnaire.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: During surgery every 15 minutes. Method of measurement: Monitoring.</prim_outcome>
      <prim_outcome>Heart rate. Timepoint: During surgery every 15 minutes. Method of measurement: Monitoring.</prim_outcome>
      <prim_outcome>Consent of the surgeon. Timepoint: After surgery. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-04</approval_date>
        <contact_name>Ethics Committee of Shiraz Medical School.</contact_name>
        <contact_address>3rd Floor, 3rd bBuiding of the Shiraz Medical School, Zand Blvd. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
